Management of Sickle Cell Trait and Alpha Thalassemia

Introduction to Sickle Cell Trait

Sickle cell trait (SCT) is considered a benign condition in most individuals, characterized by one normal beta-globin gene and one sickle beta-globin gene, with normal hemoglobin (HbA) levels of 55-65% and sickle hemoglobin (HbS) levels of 30-40%, as supported by the American Society of Anesthesiologists 1
SCT is generally considered a benign condition under normal physiological conditions, classified as "benign" in medical literature, with a strength of evidence supported by multiple sources 1, 2
Individuals with sickle cell trait have normal hemoglobin levels under standard conditions, as stated by the American Society of Anesthesiologists 1

For patients with SCT undergoing surgery, no routine pre-operative transfusion is needed, and ensuring adequate hydration and oxygenation during procedures is recommended, while avoiding prolonged hypoxemia and dehydration, as suggested by the American Society of Anesthesiologists 1
Routine screening for anemia is not necessary specifically for individuals with SCT, but if anemia is present, clinicians should investigate other common causes, such as iron deficiency, B12/folate deficiency, or chronic disease, as recommended by the American Society of Anesthesiologists 1

Complete blood count during routine visits is suggested for patients with SCT and alpha thalassemia, although no specific guideline society recommendations are provided for laboratory monitoring in the given text

Patient education regarding potential triggers that could cause complications, such as extreme dehydration, high-intensity physical activity, high altitude exposure, and severe hypoxemia, is essential for individuals with SCT and alpha thalassemia, as a general precautionary measure
Certain extreme conditions, such as extreme dehydration, high-intensity physical activity, high altitude exposure, and severe hypoxemia, can trigger complications in individuals with SCT, including exertional rhabdomyolysis, splenic infarction, renal papillary necrosis, and rare thromboembolic events 2
Athletes with SCT should follow precautionary measures, including gradual conditioning, adequate rest and hydration, and immediate cessation of activity if experiencing muscle weakness or other symptoms, as recommended by medical literature 2

Sickle cell disease (particularly HbSS) is characterized by two abnormal beta-globin genes, HbS levels of 80-95%, severe anemia with hemoglobin levels typically between 60-90 g/L, and chronic hemolysis and vaso-occlusive complications, as opposed to SCT which is generally considered benign 1